At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 128 enrolled
Drug / intervention
Depigoid +2 moredrug
Likely dose
Depigoid 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, 20 Week, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Combination With Depigoid, Versus Depigoid Only, in Adult and Adolescent Patients With Seasonal Allergic Asthma and Comorbid Seasonal Allergic Rhinoconjunctivitis - Open-label Depigoid Monotherapy Extension Periods 2007 and 2008-
In Brief
A Phase 3 clinical trial evaluating Depigoid, Omalizumab, and 1 other intervention for Allergic Asthma. Completed, enrolled 128 participants across 1 site.
Detailed Summary
Efficacy/ safety for the combination of anti-IgE (Omalizumab) and specific immunotherapy (Depigoid) in patients with not adequately controlled seasonal allergic asthma and comorbid seasonal allergic rhinoconjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Asthma
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedNov 2006
Primary CompletionAug 2008
TodayJul 2026
First PostedNov 7, 2006
Enrollment StartFeb 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.7 years ago
Interventions
Depigoiddrug
Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
Omalizumabdrug
anti-IgE (Omalizumab) given during the 2006 core study
Placebodrug
Placebo given during the 2006 core study